All In Biotech

NDA 208855 · Eli Lilly and CO

Verzenio

Abemaciclib · Oral

Priority review

Last checked: Nov 20, 2026Latest source record: Feb 26, 2018 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2018

Feb 26, 2018

Approved uses

1

Original approval plus efficacy supplements

Registered trials

248

32 Phase 3, 85 recruiting

FAERS reports

21,145

10,932 serious, 1,481 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

No structured label for this application in openFDA. Older and discontinued products often have none.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Feb 26, 2018 Original approval · Type 9 - New Indication Submitted as Distinct NDA, Consolidated with Original NDA after Approval · priority review LabelLetterReview
4 products under this application
  • VERZENIO · ABEMACICLIB 200MG · TABLET, ORAL · Prescription
  • VERZENIO · ABEMACICLIB 100MG · TABLET, ORAL · Prescription
  • VERZENIO · ABEMACICLIB 150MG · TABLET, ORAL · Prescription
  • VERZENIO · ABEMACICLIB 50MG · TABLET, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Abemaciclib" as an intervention, any sponsor and status, largest first.

All 248 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • diarrhoea6,577
  • fatigue2,834
  • nausea2,345
  • vomiting1,196
  • malignant neoplasm progression1,148
  • decreased appetite1,021
  • asthenia941
  • death811
  • constipation767
  • white blood cell count decreased761
  • drug ineffective752
  • abdominal pain upper735

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20142
20154
20164
201725
2018850
20191,657
20201,648
20211,496
20222,192
20232,788
20243,399
20253,735
20263,345

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Verzenio (Abemaciclib)

2024 spending

$1.06B

Beneficiaries

11,239

71,933 claims

Per beneficiary

$94,026

$268.49 per unit

View as table
YearSpending
2020$286,188,073
2021$324,570,465
2022$474,171,738
2023$756,850,867
2024$1,056,757,309

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 164 on PubMed

Sponsor: Eli Lilly

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.